NeuroPace heads into its third-quarter report with two stories pulling in opposite directions. The core business of treating adult focal epilepsy with its RNS system keeps growing at roughly 20%, with margins and losses moving the right way. The catalyst that was supposed to make 2026 a breakout year, approval to treat idiopathic generalized epilepsy (IGE), hit a wall in late July when the FDA said the application was not approvable in its current form. This report is the first full look at whether the base business can hold investor attention while the regulatory path is rebuilt.

Wall Street expects a loss of 6 cents a share on revenue of about $27.1 million. On paper that is a 1.1% decline from the $27.4 million reported a year ago, but the comparison is likely distorted. The Dixie Medical business is now reported as discontinued operations, so the apparent contraction probably says more about the shape of the reported numbers than about demand for RNS. The better yardstick is the sequential step: revenue was $22.8 million last quarter, so consensus calls for a sizable jump. That fits management's full-year outlook of $99.5 million to $101.5 million, which was nudged up last quarter and implies a heavier second half. With the Street's annual estimate near $100 million, consensus sits comfortably inside the range, so a modest beat would confirm the plan rather than reset it. The Earnings Whisper of a 1-cent loss is notably better than consensus, suggesting some believe operating discipline will narrow the loss more than published models assume.

That discipline was the quiet highlight of the last call. Operating expenses rose only about 3% while revenue grew 17%, the adjusted EBITDA loss shrank to $2.8 million from $4.9 million a year earlier, and management raised its gross margin target to 82% to 83% and trimmed its full-year EBITDA loss outlook to $7.5 million to $8.5 million. Validation this quarter would look like RNS growth staying at or above 20%, new highs again in active prescribers, accounts, and patient pipeline, and margins tracking toward the upper half of guidance. A challenge would come if RNS growth slips into the mid-teens. Growth has already cooled from 31% in the year-ago quarter, and management blamed tough comparisons. That explanation weakens if the slowdown persists against an easier base.

The IGE update may matter more than any line item. Management was pursuing a formal dispute process with the FDA and expected a meeting within weeks of the last call. Investors deserve clarity on whether that meeting happened, what the agency wants on clinical benefit across patient subgroups and the meaningfulness of reductions in generalized tonic-clonic seizures, and whether a new data analysis or study is required. Encouraging 24-month Nautilus data showing a 100% median reduction in those seizures among evaluable patients gives the company an argument, but the timeline is now in regulators' hands. Any sign of a lengthy delay would pressure expectations for roughly 23% growth in 2027. Secondary progress, including early uptake of the ECOG Assistant AI tool and the planned remote care submission by year end, could help fill the narrative gap.

The market has priced in skepticism. Shares have fallen about 13% since the last report, trailing the S&P 500 by more than 10 percentage points, and sentiment has turned more bearish than it was a quarter ago. At $12.31, the stock trades well below its 200-day moving average near $14.94, is hovering just above its post-earnings low of $12.00, and sits beneath the prior quarter's trough.

That sets a low bar for the numbers but a high bar for credibility. If NeuroPace delivers 20%-plus RNS growth, holds its margin gains, and offers a concrete, believable IGE roadmap, the case that the core business is undervalued gets stronger. If growth softens while the FDA path stays murky, the stock lacks an obvious reason to recover.